Home Cart Sign in  
Chemical Structure| 492431-11-5 Chemical Structure| 492431-11-5

Structure of 492431-11-5

Chemical Structure| 492431-11-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 492431-11-5 ]

CAS No. :492431-11-5
Formula : C13H19ClN4O2
M.W : 298.77
SMILES Code : C(=O)(OC(C)(C)C)N1CCN(CC1)C2=CC=C(N=N2)Cl
MDL No. :MFCD05864738
InChI Key :MIXODQAAOQHDTG-UHFFFAOYSA-N
Pubchem ID :21925370

Safety of [ 492431-11-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 492431-11-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 20
Num. arom. heavy atoms 6
Fraction Csp3 0.62
Num. rotatable bonds 4
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 84.24
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

58.56 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

3.05
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.92
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.43
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.79
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.22
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.88

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.86
Solubility 0.412 mg/ml ; 0.00138 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.77
Solubility 0.503 mg/ml ; 0.00169 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.94
Solubility 0.343 mg/ml ; 0.00115 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.76 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.82

Application In Synthesis of [ 492431-11-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 492431-11-5 ]

[ 492431-11-5 ] Synthesis Path-Downstream   1~21

  • 1
  • 2-(6-hydroxy-2,3-dihydrobenzo[1,4]oxazin-4-yl)-5,5-dimethyl-5,6-dihydro-4H-benzothiazol-7-one [ No CAS ]
  • [ 492431-11-5 ]
  • C30H36N6O5S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With caesium carbonate; In N,N-dimethyl-formamide; at 120℃; for 2.0h;Microwave irradiation; EXAMPLE 92; 5,5-Dimethyl-2-(6-[r6-piperazin-l-ylpyridazin-3-yl)oxy]-2,3-dihydro-4H-L4- benzoxazin-4-vU -5.6-dihydro- 1 ,3 -benzothiazol-7(4/f)-one; A mixture of 3,6-dichloropyridazine (0.60 g, 3.24 mmol), l-5(9C-piperazine (0.48 g, 3.24 mmol) and DIPEA (0.60 tnL, 3.24 mmol) in THF (20 mL) was heated to 14O0C under microwave irradiation for 3h. After cooling to r.t. it was concentrated in vacuo and purified by column chromatography (SiO2, 0-50% EtOAc in heptane) to give a white solid. A mixture of this material (crude pyridazinyl piperazine, 45 mg, 0.15 mmol),Example 6 (50 mg, 0.15 mmol) and cesium carbonate (98 mg, 0.3 mmol) in DMF (4 mL) was heated to 12O0C under microwave irradiation for 2h. After cooling to r.t. the mixture was concentrated in vacuo and purified by prep HPLC to give an off-white solid (26 mg, 30%). deltaH (CDCl3) 1.13 (6H, s), 1.48 (9H, s), 2.41 (2H, s), 2.74 (2H, s), 3.14 (8H, br.s), 4.15-4.24 (2H, m), 4.30-4.38 (2H5 m), 6.89-7.00 (2H, m), 7.26 (2H, s), 7.89 (IH, d, J 2.4 Hz). LCMS (ES+) 593 (M+H)+.
  • 2
  • [ 141-30-0 ]
  • [ 57260-71-6 ]
  • [ 492431-11-5 ]
YieldReaction ConditionsOperation in experiment
88% With N-ethyl-N,N-diisopropylamine; In 1,4-dioxane; at 80℃; Synthesis of tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate To a solution of 3,6-dichloropyridazine (Sigma-Aldrich, St. Louis, Mo.) (57.3 g, 385 mmol) in 1,4-dioxane (250 mL) were added tert-butyl piperazine-1-carboxylate (Sigma-Aldrich) (71.6 g, 358 mmol) and N,N-diisopropylethylamine (66.9 mL, 385 mmol). The mixture was stirred overnight at 80 C. then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (3 L) and washed with 10% citric acid, water, and brine. The organic layer was concentrated and the residue was re-crystallized in ethyl acetate to provide tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate as an off-white solid (101 g, 88% yield). 1H NMR (400 MHz, CDCl3) delta ppm 1.25 (9H, s), 3.26-3.47 (8H, m), 6.67 (1H, d, J=9.6 Hz), 7.00 (1H, d, J=9.6 Hz); MS (ESI) m/z: 299.0 [M+H]+.
70% With triethylamine; In N,N-dimethyl-formamide; at 80℃; A solution of 3,6-dichloropyridazine (5.01 g, 33.6 mmol) and tert-butyl piperazine-1-carboxylate (6.88g, 37.0 mmol) in DMF (50 mL) was added triethylamine (11.7 mL, 50.4 mmol) and stirred at 80C overnight. The resultant reaction mixture was cooled to room temperature, and water was added to the mixture. The mixture was extracted three times with a solvent mixture of dichloromethane and methanol (95:5) (50 mL). The resultant organic phases were combined together and dried over anhydrous magnesium sulfate. The resultant solid was separated by filtration, and the filtrate was then concentrated under reduced pressure. The resultant crude product was washed with diethyl ether to yield the title compound (7.0 g, 70%).
70% With triethylamine; In N,N-dimethyl-formamide; at 80℃; 3,6-Dichloropyridazine (5.01 g, 33.6 mmol) and tert-butyl piperazine-1-carboxylate (6.88 g, 37.0 mmol) were dissolved in DMF (50 mL). Triethylamine (11.7 mL, 50.4 mmol) was added to the solution. The resulting mixture was stirred at 80C overnight. The reaction mixture was cooled to room temperature and water was added. The solution was extracted with a 95:5 mixed solvent (50 mL) of dichloromethane and methanol three times. The combined organic phase was dried over anhydrous magnesium sulfate. The solid was filtered out, and the filtrate was concentrated under reduced pressure. The crude product was washed with diethyl ether to give the title compound (7.0 g, yield: 70%).
63% With triethylamine; In toluene; at 110℃; for 16.0h; Preparation of tert-Butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate 6-3: (1202) (1203) A stirred mixture of 3,6-dichloropyridazine 6-1 (2.0 g, 13.4 mmol), tert-butyl piperazine- 1-carboxylate 6-2 (3.72 g, 20.0 mmol) and triethylamine (2.78 mL, 20.0 mmol) in toluene (20mL) was heated at 110 C for 16 h. After complete consumption of 6-1 as evident from TLC, the volatiles were stripped off, residue partitioned between ethyl acetate and water, combined organic extracts evaporated to afford a crude residue which was purified column chromatography (elution with 30% ethyl acetate/Hexane) to afford tert-butyl 4-(6-chloropyridazin-3- yl)piperazine-1-carboxylate 6-3 (2.52 g, 8.46 mmol, 63.0 %) as an off-white solid. LC MS: ES+ 299.2
With triethylamine; In butan-1-ol; for 5.0h;Heating / reflux; A mixture of 13.52 g of tert-butyl 1-piperazinecarboxylate, 10.81 g of 3,6-dichloropyridazine and 20 ml of triethylamine in 100 ml of n-butanol is heated at reflux for 5 hours. It is concentrated under vacuum and the residue is chromatographed on silica gel, eluting with a DCM/AcOEt (90/10; v/v) mixture. This gives 14 g of the expected product, which is used as it is.
With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; at 140℃; for 3.0h;Microwave irradiation; EXAMPLE 92; 5,5-Dimethyl-2-(6-[r6-piperazin-l-ylpyridazin-3-yl)oxy]-2,3-dihydro-4H-L4- benzoxazin-4-vU -5.6-dihydro- 1 ,3 -benzothiazol-7(4/f)-one; A mixture of 3,6-dichloropyridazine (0.60 g, 3.24 mmol), l-5(9C-piperazine (0.48 g, 3.24 mmol) and DIPEA (0.60 tnL, 3.24 mmol) in THF (20 mL) was heated to 14O0C under microwave irradiation for 3h. After cooling to r.t. it was concentrated in vacuo and purified by column chromatography (SiO2, 0-50% EtOAc in heptane) to give a white solid. A mixture of this material (crude pyridazinyl piperazine, 45 mg, 0.15 mmol),Example 6 (50 mg, 0.15 mmol) and cesium carbonate (98 mg, 0.3 mmol) in DMF (4 mL) was heated to 12O0C under microwave irradiation for 2h. After cooling to r.t. the mixture was concentrated in vacuo and purified by prep HPLC to give an off-white solid (26 mg, 30%). deltaH (CDCl3) 1.13 (6H, s), 1.48 (9H, s), 2.41 (2H, s), 2.74 (2H, s), 3.14 (8H, br.s), 4.15-4.24 (2H, m), 4.30-4.38 (2H5 m), 6.89-7.00 (2H, m), 7.26 (2H, s), 7.89 (IH, d, J 2.4 Hz). LCMS (ES+) 593 (M+H)+.
With triethylamine; In butan-1-ol; for 5.0h;Heating / reflux; A mixture of 13.52 g of tert-butyl 1-piperazinecarboxylate, 10.81 g of 3,6-dichloro-pyridazine and 20 ml of triethylamine in 100 ml of n-butanol is refluxed for 5 hours. The mixture is concentrated under vacuum and the residue is chromatographed on silica gel, eluting with a DCM/EtOAc mixture (90/10; v/v). 14 g of the expected product are obtained, and are used without further purification.
With N-ethyl-N,N-diisopropylamine; In tert-butyl alcohol; at 100 - 150℃; for 0.833333h;Microwave irradiation; Intermediate 141 ,1 -dimethylethyl 4-(6-chloro-3-pyridazinyl)-1 -piperazinecarboxylate In a microwave vial were mixed: 1 ,1 -dimethylethyl 1 -piperazinecarboxylate(135 mg, 0.725 mmol, available from Fluka), 3,6-dichloropyridazine (90 mg, 0.604 mmol, available from Alfa Aesar) and DIPEA (0.137 mL, 0.785 mmol) in Tert-Butanol (2 mL). The reaction was stirred and heated in an Emrys Optimizer microwave at 100C for 20 mins then for 30 mins at 150C. The reaction mixture was partitioned between EtOAc (20mL) and water (20mL) and the organic layer washed with brine (20mL) before being dried through an hydrophobic frit and concentrated. The residue was dissolved in DCM and purified by SP4 on a 12+M silica cartridge using a gradient of 10-50% EtOAc in cyclohexane. The appropriate fractions were collected and concentrated to yield the desired product as a white solid, 1 ,1 -dimethylethyl 4-(6-chloro-3-pyridazinyl)-1 - piperazinecarboxylate (1 14.2 mg). LCMS (Method C): Rt = 0.85, MH+ = 299
With N-ethyl-N,N-diisopropylamine; In tert-butyl alcohol; at 100 - 150℃; for 0.833333h;Microwave irradiation; In a microwave vial were mixed: 1,1-dimethylethyl 1-piperazinecarboxylate (135 mg, 0.725 mmol, available from Fluke), 3,6-dichloropyridazine (90 mg, 0.604 mmol, available from Alfa Aesar) and DIPEA (0.137 mL, 0.785 mmol) in Tert-Butanol (2 mL). The reaction was stirred and heated in an Emrys Optimizer microwave at 100 C. for 20 mins then for 30 mins at 150 C. The reaction mixture was partitioned between EtOAc (20 mL) and water (20 mL) and the organic layer washed with brine (20 mL) before being dried through an hydrophobic frit and concentrated. The residue was dissolved in DCM and purified by SP4 on a 12+M silica cartridge using a gradient of 10-50% EtOAc in cyclohexane. The appropriate fractions were collected and concentrated to yield the desired product as a white solid, 1,1-dimethylethyl 4-(6-chloro-3-pyridazinyl)-1-piperazinecarboxylate (114.2 mg). LCMS (Method C): Rt=0.85, MH+=299

  • 3
  • [ 492431-11-5 ]
  • [ 492431-12-6 ]
YieldReaction ConditionsOperation in experiment
With hydrogen;palladium 10% on activated carbon; In DMF (N,N-dimethyl-formamide); ethanol; at 20℃; under 760.051 Torr; A mixture of 10.5 g of the compound obtained in the preceding step and 2.5 g of 10% palladium on carbon in 30 ml of DMF and 250 ml of EtOH is hydrogenated at AT under atmospheric pressure overnight. The catalyst is filtered off and the filtrate is concentrated under vacuum. The residue is chromatographed on silica gel, eluting with a DCM/MeOH (97/3 to 90/10; v/v) mixture. This gives 9.1 g of the expected product, which is used as it is.
With hydrogen;palladium 10% on activated carbon; In DMF (N,N-dimethyl-formamide); ethanol; at 20℃; under 760.051 Torr; A mixture of 10.5 g of the compound obtained in the preceding step and 2.5 g of 10% palladium-on-charcoal in 30 ml of DMF and 250 ml of EtOH is hydrogenated overnight at RT and atmospheric pressure. The catalyst is filtered off and the filtrate is concentrated under vacuum. The residue is chromatographed on silica gel, eluting with a DCM/MeOH mixture of from (97/3; v/v) to (90/10; v/v). 9.1 g of the expected product are obtained, and are used without further purification.
  • 4
  • [ 492431-11-5 ]
  • 3-chloro-6-(1-piperazinyl)pyridazine trihydrochloride [ No CAS ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride; In methanol; at 20℃; A mixture of 2.96 g of the compound obtained in step A of preparation 3.3 and 30 ml of a 6N solution of HCl in MeOH is left with stirring in AT overnight. The reaction mixture is concentrated under vacuum, the residue is taken up in DCM a number of times and each time the solvent is evaporated under vacuum. This gives 2.6 g of the expected product, which is used as it is.
  • 5
  • [ 492431-11-5 ]
  • [ 56392-83-7 ]
YieldReaction ConditionsOperation in experiment
With trifluoroacetic acid; In dichloromethane; at 20℃; for 0.75h; A. To an ice cold solution of 4-(6-chloropyridazin-3-yl)piperazine-1- carboxylic acid tert-butyl ester (2.00 g, 6.69 mmol) in dichloromethane (10 mL) was carefully added trifluoroacetic acid (2 mL). The mixture was stirred for 45 minutes at room temperature and then concentrated in vacuo to afford the crude 3-chloro-6- piperazin-1-ylpyridazine (~1.0 g) which was used in the next reaction without further purification. MS (ES+) m/z 199.1 (M+1 ).
  • 6
  • [ 1000798-21-9 ]
  • [ 492431-11-5 ]
  • [ 1082503-87-4 ]
  • 7
  • [ 1000793-50-9 ]
  • [ 492431-11-5 ]
  • [ 1082503-85-2 ]
  • 8
  • [ 492431-11-5 ]
  • [ 1169698-72-9 ]
  • [ 1169698-83-2 ]
YieldReaction ConditionsOperation in experiment
With sodium t-butanolate;tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; In 1,4-dioxane; at 120℃; for 6.0h; A mixture of tert-butyl 4- (6-chloropyridazin-3-yl)piperazine-l-carboxylate (0.060 g, 0.20 mmol), compound 83 (0.054 g, 0.20 mmol), Xantphos (0.017 g, 0.030 mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), and sodium tert-butoxide (0.029 g, 0.30 mmol) in dioxane was purged with nitrogen gas for 1 minute. The reaction was heated at 12O0C for 6 hours and then cooled to room temperature. The solvent was removed by filtration. The residue was washed with 2 x ImI dioxane. The product was then dissolved in 1OmL methanol/DCM (1 :1) and concentrated. The crude material was re-dissolved in 4mL methanol and purified on a C-18 reversephase column (150 x 30 mm, 4 micro) using Mass directed preperative HPLC and gradient elution of acetonitrile in water containing 0.1%TFA to give the title compound 162. LCMS-ESI (POS), M/Z, M+l: 532.3
  • 9
  • [ 1013-88-3 ]
  • [ 492431-11-5 ]
  • [ 1256963-23-1 ]
YieldReaction ConditionsOperation in experiment
76% With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 100℃; Tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate synthesized in Reference Example 17 (59.8 mg, 0.20 mmol, benzophenone imine (43.5 mg, 0.24 mmol), tris(dibenzylideneacetone)dipalladium (9.2 mg, 0.010 mmol), BINAP (12.5 mg, 0.020 mmol), and cesium carbonate (130.3 mg, 0.40 mmol) were suspended in toluene (1.0 mL), and the suspension was stirred at 100C overnight. The resultant reaction mixture was cooled to room temperature and then filtered through Celite, and the Celite was washed with ethyl acetate. The filtrate was washed with saturated brine and dried over anhydrous magnesium sulfate, and the solid was separated by filtration. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to yield the title compound (67 mg, 76%).
76% With tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 100℃; The <strong>[492431-11-5]tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate</strong> (59.8 mg, 0.20 mmol) prepared in Referential Example 14, benzophenone imine (43.5 mg, 0.24 mmol), tris(dibenzylideneacetone)dipalladium (9.2 mg, 0.010 mmol), BINAP (12.5 mg, 0.020 mmol) and cesium carbonate (130.3 mg, 0.40 mmol) were suspended in toluene (1.0 mL). The reaction mixture was stirred at 100C overnight. The reaction mixture was cooled to room temperature and filtered through a Celite pad. The Celite pad was washed with ethyl acetate. The filtrate was washed with saturated brine, and dried over anhydrous magnesium sulfate. The solid was filtered out, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (67 mg, yield: 76%).
  • 11
  • [ 492431-11-5 ]
  • [ 1256963-27-5 ]
  • 12
  • [ 492431-11-5 ]
  • [ 22821-77-8 ]
  • [ 1379522-31-2 ]
  • 13
  • [ 492431-11-5 ]
  • [ 1401034-45-4 ]
  • C29H37N9O2 [ No CAS ]
  • 14
  • [ 492431-11-5 ]
  • 2-hydroxy-4-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzaldehyde [ No CAS ]
  • tert-butyl 4-(6-(5-formyl-4-hydroxy-2-methoxyphenyl)pyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
21.43% With dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane; potassium phosphate; tris-(dibenzylideneacetone)dipalladium(0); In 1,4-dioxane; water; at 100℃; for 18.0h; The title compound (107 mg, 0.258 mmol, 21.43 % yield) was prepared following GENERAL METHOD 9-1 for Suzuki reaction of ferf-butyl 4-(6-chloropyridazin-3-yl)piperazine-1- carboxylate (4.7 g, 16.62 mmol) and Intermediate 15 (500 mg, 1 .8 mmol). Dioxane was removed in vacuo and EtOAc/DCM and water were added. The layers were separated and the aqueous layer was washed with DCM. The combined organics were dried over MgS04, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography (5-80% EtOAc/Hep). MS (M+1 ) = 415.5. 1H NMR (400 MHz, Chloroform-d) delta 1 1 .57-1 1 .51 (m, 1 H), 9.85 - 9.79 (m, 1 H), 8.26-8.20 (m, 1 H), 7.82-7.73 (m, 1 H), 6.97-6.89 (m, 1 H), 6.58 - 6.52 (m, 1 H), 3.96- 3.90 (m, 3H), 3.70 (s, 4H), 3.65-3.56 (m, 4H), 1 .53-1.47 (m, 9H). GENERAL METHOD 9-1 for Suzuki reaction Representative Procedure for Suzuki Coupling with Pd2(dba)3 and SPhos A mixture of a chloropyridazine intermediate, such as Intermediate 1 (1.0 equivalent), a boronic acid reagent (1.5-2 equivalents), SPhos (0.2 equivalents), Pd2(dba)3 (0.05 equivalents), and K3P04 (3 equivalents) in 4:1 dioxane/water (0.2 M) was heated in an oil bath at 100 C for 18 h. The mixture was concentrated in vacuo and the crude residue was purified via silica gel chromatography (1 -30% MeOH/DCM, column pretreated with TEA).
  • 15
  • [ 492431-11-5 ]
  • tert-butyl 4-(6-(5-formyl-2-methoxy-4-(((trifluoromethyl)sulfonyl)oxy)-phenyl)pyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
  • 16
  • [ 492431-11-5 ]
  • tert-butyl 4-(6-(5-formyl-2-methoxy-4-(prop-1-yn-1-yl)phenyl)pyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
  • 17
  • [ 492431-11-5 ]
  • tert-butyl 4-(6-(6-methoxy-3-methylisoquinolin-7-yl)pyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
  • 18
  • [ 571189-64-5 ]
  • [ 492431-11-5 ]
  • tert-butyl 4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; sodium t-butanolate; In 1,4-dioxane; at 150℃; for 1.0h;Microwave irradiation; Synthesis of tert-butyl 4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridazin-3-yl)piperazine-1-carboxylate To a solution of acetyl-2-amino-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one (114 mg, 0.40 mmol) in 1,4-dioxane (4 mL) were added <strong>[492431-11-5]tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate</strong> (143 mg, 0.48 mmol), tris(dibenylideneacetone)dipalladium (0) (18.4 mg, 0.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg, 0.06 mmol), sodium t-butoxide (58 mg, 0.60 mmol). The mixture thus obtained was heated for 1 h at 150 C. under microwave irradiation. The reaction mixture was passed through short pack silica gel column and was concentrated to give a crude product as a yellow solid (153 mg, purity: 50-60%) which was used in next step without any further purification. MS (ESI) m/z: 549.3 [M+H]+.
  • 19
  • [ 492431-11-5 ]
  • [ 145276-53-5 ]
YieldReaction ConditionsOperation in experiment
65.9% With acetic acid; at 120℃; for 16.0h; Preparation of 6-(Piperazin-1-yl)pyridazin-3(2H)-one 6-4: (1204) A solution of <strong>[492431-11-5]tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate</strong> 6-3 (2.2 g, 7.36 mmol) in acetic acid (20mL) was heated at 120 C for 16 h. After complete consumption of Cpd-3 as evident from TLC, the volatiles were stripped off, residue partitioned between ethyl acetate and water, combined organic extracts evaporated to afford a crude residue which was purified over neutral alumina (elution with 30% methanol/DCM)to afford 6-(piperazin-1- yl)pyridazin-3(2H)-one 6-4 (871 mg, 4.83 mmol, 65.9 %) as a brown solid. LC MS: ES+ 181.1
  • 20
  • [ 492431-11-5 ]
  • [ 1103507-90-9 ]
  • 21
  • [ 492431-11-5 ]
  • tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-6-oxo-1,6-dihydropyridazin-3-yl)piperazine-1-carboxylate [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 492431-11-5 ]

Chlorides

Chemical Structure| 208167-83-3

A333376 [208167-83-3]

tert-Butyl 4-(2-chloroethyl)piperazine-1-carboxylate

Similarity: 0.53

Chemical Structure| 954238-81-4

A165712 [954238-81-4]

tert-Butyl (2-amino-3-chlorophenyl)carbamate

Similarity: 0.53

Chemical Structure| 171178-45-3

A228692 [171178-45-3]

tert-Butyl (6-chloropyridin-3-yl)carbamate

Similarity: 0.52

Chemical Structure| 870535-27-6

A264072 [870535-27-6]

tert-Butyl 4-chloro-2-(hydroxymethyl)-1H-indole-1-carboxylate

Similarity: 0.51

Chemical Structure| 886767-49-3

A261815 [886767-49-3]

tert-Butyl 3-(4-chlorophenyl)piperazine-1-carboxylate

Similarity: 0.51

Amides

Chemical Structure| 170911-92-9

A396431 [170911-92-9]

tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate

Similarity: 0.60

Chemical Structure| 197638-83-8

A119861 [197638-83-8]

1-Boc-4-(4-Formylphenyl)piperazine

Similarity: 0.56

Chemical Structure| 1257849-25-4

A175868 [1257849-25-4]

1-Boc-4-(3-Formylphenyl)piperazine

Similarity: 0.55

Chemical Structure| 1285278-84-3

A106849 [1285278-84-3]

tert-Butyl 3-(phenylamino)azetidine-1-carboxylate

Similarity: 0.54

Chemical Structure| 196811-66-2

A202451 [196811-66-2]

tert-Butyl 4-carbamothioylpiperazine-1-carboxylate

Similarity: 0.54

Related Parent Nucleus of
[ 492431-11-5 ]

Piperazines

Chemical Structure| 170911-92-9

A396431 [170911-92-9]

tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate

Similarity: 0.60

Chemical Structure| 197638-83-8

A119861 [197638-83-8]

1-Boc-4-(4-Formylphenyl)piperazine

Similarity: 0.56

Chemical Structure| 1257849-25-4

A175868 [1257849-25-4]

1-Boc-4-(3-Formylphenyl)piperazine

Similarity: 0.55

Chemical Structure| 196811-66-2

A202451 [196811-66-2]

tert-Butyl 4-carbamothioylpiperazine-1-carboxylate

Similarity: 0.54

Chemical Structure| 76535-74-5

A295373 [76535-74-5]

tert-Butyl piperazine-1-carboxylate hydrochloride

Similarity: 0.54

Pyridazines

Chemical Structure| 51047-56-4

A696123 [51047-56-4]

3-Piperazin-1-yl-pyridazine

Similarity: 0.53